Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Treatments

Topic: Disease mechanisms in lab and animal studies

Plain-language summary

Alzheimer's disease is one of the most common causes of dementia. It is believed that the aggregation of short A β ‐peptides to form oligomeric and protofibrillar amyloid assemblies plays a central role for disease‐relevant neurotoxicity. In recent years, passive immunotherapy has been introduced as a potential treatment strategy with anti‐amyloid antibodies binding to A β ‐amyloids and inducing their subsequent degradation by the immune system. Although so far mostly unsuccessful in clinical studies, the high‐dosed application of the monoclonal antibody Aducanumab has shown therapeutic potential that might be attributed to its much greater affinity to A β ‐aggregates vs monomeric A β ‐peptides. In order to better understand how Aducanumab interacts with aggregated A β ‐forms compared to monomers, we have generated structural model complexes based on the known structure of Aducanumab in complex with an A β 2 − 7 ‐eptitope. Structural models of Aducanumab bound to full‐sequence A β 1 − 40 ‐monomers, oligomers, protofilaments and mature fibrils were generated and investigated using extensive molecular dynamics simulations to characterize the flexibility and possible additional interactions. Indeed, an aggregate‐specific N‐terminal binding motif was found in case of Aducanumab binding to oligomers, protofilaments and fibrils that is located next to but not overlapping with the epitope binding site found in the crystal structure with A β 2 − 7 . Analysis of binding energetics indicates that this motif binds weaker than the epitope but likely contributes to Aducanumab's preference for aggregated A β ‐species. The predicted aggregate‐specific binding motif could potentially serve as a basis to reengineer Aducanumab for further enhanced preference to bind A β ‐aggregates vs monomers.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Frost, C. V., & Zacharias, M. (2020). From monomer to fibril: Abeta‐amyloid binding to Aducanumab antibody studied by molecular dynamics simulation. Proteins: Structure, Function, and Bioinformatics. https://doi.org/10.1002/prot.25978

Vancouver

Frost CV, Zacharias M. From monomer to fibril: Abeta‐amyloid binding to Aducanumab antibody studied by molecular dynamics simulation. Proteins: Structure, Function, and Bioinformatics. 2020. doi:10.1002/prot.25978.

BibTeX

@article{frost2020-87e1c4ad,
  author  = {Frost, Christina V. and Zacharias, Martin},
  title   = {{From monomer to fibril: Abeta‐amyloid binding to Aducanumab antibody studied by molecular dynamics simulation}},
  journal = {Proteins: Structure, Function, and Bioinformatics},
  year    = {2020},
  doi     = {10.1002/prot.25978},
  url     = {https://doi.org/10.1002/prot.25978}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 38/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 1 of 2; Free to read left out, no data. 21 of the 56 points it could be judged on, which is 38 of 100. Total 38 of 100.21 of the 56 points we could judge = 38 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 21 of the 56 points we could judge it on, which is 38 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Proteins: Structure, Function, and Bioinformatics)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2020 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read — / 2 Access not recorded — left out of this score
Points 21 / 56 Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 21 of the 56 points we could judge it on is 38 out of 100.
Total 38 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments from nearby years

Also tagged “presenilin”

343 studies in the library carry the topic tag “presenilin”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 343 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →